ZIMMERMANN, Frederik M, Victoria Y DING, Nico H J PIJLS, Zsolt PIROTH, Albert H M VAN STRATEN, Laszlo SZEKELY, Giedrius DAVIDAVICIUS, Gintaras KALINAUSKAS, Samer MANSOUR, Rajesh KHARBANDA, Nikolaos OSTLUND-PAPADOGEORGOS, Adel AMINIAN, Keith G OLDROYD, Nawwar AL-ATTAR, Nikola JAGIC, Jan-Henk E DAMBRINK, Petr KALA, Oskar ANGERAS, Philip MACCARTHY, Olaf WENDLER, Filip CASSELMAN, Nils WITT, Kreton MAVROMATIS, Steven E S MINER, Jaydeep SARMA, Thomas ENGSTROM, Evald H CHRISTIANSEN, Pim A L TONINO, Michael J REARDON, Hisao OTSUKI, Yuhei KOBAYASHI, Mark A HLATKY, Kenneth W MAHAFFEY, Manisha DESAI, Y Joseph WOO, Alan C YEUNG, De Bruyne BERNARD a William F FEARON. Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial. Circulation. Philadelphia: Lippincott Williams Wilkins, 2023, roč. 148, č. 12, s. 950-958. ISSN 0009-7322. Dostupné z: https://dx.doi.org/10.1161/CIRCULATIONAHA.123.065770.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial
Autoři ZIMMERMANN, Frederik M, Victoria Y DING, Nico H J PIJLS, Zsolt PIROTH, Albert H M VAN STRATEN, Laszlo SZEKELY, Giedrius DAVIDAVICIUS, Gintaras KALINAUSKAS, Samer MANSOUR, Rajesh KHARBANDA, Nikolaos OSTLUND-PAPADOGEORGOS, Adel AMINIAN, Keith G OLDROYD, Nawwar AL-ATTAR, Nikola JAGIC, Jan-Henk E DAMBRINK, Petr KALA (203 Česká republika, domácí), Oskar ANGERAS, Philip MACCARTHY, Olaf WENDLER, Filip CASSELMAN, Nils WITT, Kreton MAVROMATIS, Steven E S MINER, Jaydeep SARMA, Thomas ENGSTROM, Evald H CHRISTIANSEN, Pim A L TONINO, Michael J REARDON, Hisao OTSUKI, Yuhei KOBAYASHI, Mark A HLATKY, Kenneth W MAHAFFEY, Manisha DESAI, Y Joseph WOO, Alan C YEUNG, De Bruyne BERNARD a William F FEARON.
Vydání Circulation, Philadelphia, Lippincott Williams Wilkins, 2023, 0009-7322.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 37.800 v roce 2022
Kód RIV RIV/00216224:14110/23:00133683
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1161/CIRCULATIONAHA.123.065770
UT WoS 001078473500004
Klíčová slova anglicky coronary artery bypass; drug-eluting stents; percutaneous coronary intervention
Štítky 14110211, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 29. 2. 2024 08:28.
Anotace
BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98-1.83]; P=0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6-1.7]; P=0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4-1.7]; P=0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1-2.7]; P=0.02). CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02100722.
VytisknoutZobrazeno: 17. 5. 2024 17:59